IMCgp100-202
16 Oct 2017
IMCgp100-202
NCT03070392
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore
A phase II randomized, open-label, multi-centre study of the safety and efficacy of IMCgp100 compared with Investigator choice in HLA-A*0201 positive patients with previously untreated advanced uveal melanoma.
Cancer Type | Melanoma/Skin |
---|---|
Trial Type | Treatment |
Phase | Phase II |
Age Range | 18+ years |
Sex | Both |
Tumour Stream | Uveal Melanoma |
Cancer Stage | Locally Recurrent or Locally Advanced |
Anticipated Start Date | 2017-10-16 |
Anticipated End Date | tbc |
Hospital | Royal Adelaide Hospital |
---|---|
Clinical Trial Coordinator | Anne Milton |
anne.milton@sa.gov.au | |
Phone | 08 7074 2342 |
Principal Investigator | Professor Michael Brown |
Recruitment Status | Recruiting |